ANDREW SHER to Radiopharmaceuticals
This is a "connection" page, showing publications ANDREW SHER has written about Radiopharmaceuticals.
Connection Strength
0.505
-
Assessment of Sequential PET/MRI in Comparison With PET/CT of Pediatric Lymphoma: A Prospective Study. AJR Am J Roentgenol. 2016 Mar; 206(3):623-31.
Score: 0.124
-
Whole-body positron emission tomography-magnetic resonance in breast cancer. Semin Roentgenol. 2014 Oct; 49(4):313-20.
Score: 0.111
-
Positron emission tomography/magnetic resonance imaging of the breast. Semin Roentgenol. 2014 Oct; 49(4):304-12.
Score: 0.109
-
Peptide receptor radionuclide therapy for treatment of metastatic neuroendocrine tumors in children. Pediatr Blood Cancer. 2021 07; 68(7):e29056.
Score: 0.044
-
Comparison of the diagnostic accuracy of PET/MRI to PET/CT-acquired FDG brain exams for seizure focus detection: a prospective study. Pediatr Radiol. 2017 Oct; 47(11):1500-1507.
Score: 0.034
-
Early response monitoring of receptor tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma using [F-18]fluorothymidine-positron emission tomography-magnetic resonance. Semin Roentgenol. 2014 Jul; 49(3):238-41.
Score: 0.028
-
Positron emission tomography-magnetic resonance imaging in the evaluation of brain tumors: current status and future prospects. Semin Roentgenol. 2014 Jul; 49(3):275-89.
Score: 0.028
-
PET/MRI in lung cancer. Semin Roentgenol. 2014 Oct; 49(4):291-303.
Score: 0.028